Company intelligence / Profile preview

EvviVax

Rome, Italy

Ownership: Private
Development stage: Other

Overview

EvviVax has demonstrated preclinical efficacy of DNA cancer vaccines (e.g., Tel-eVax) in animal models with tumor reduction and successful immune response; its COVID-19 veterinary vaccine showed neutralizing antibodies in preclinical/early clinical trials for pets.

Therapeutic areas: OncologyInfectious Diseases
Modalities: DNA vaccineVaccineViral vectorLipid nanoparticle delivery therapyGene therapy
Industry: Biotech

Drug pipeline

3 assets

Tel-eVax

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

TakisApplied DNA Sciences/LineaRx

Beyond the preview

Go deeper on EvviVax.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EvviVax.

Explore the full profile